Alx Oncology Holdings (ALXO) Free Cash Flow (2019 - 2026)
Alx Oncology Holdings recorded quarterly Free Cash Flow of -$18.7 million in Q1 2026, up 1.74% quarter-over-quarter from -$19.0 million in Q4 2025, and up 24.37% year-over-year from -$15.0 million in Q1 2025.
Alx Oncology Holdings' Free Cash Flow history runs 8 years deep, the most recent figure standing at -$18.7 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 24.37% year-over-year to -$18.7 million; the TTM figure through Mar 2026 stood at -$78.3 million (up 28.15% YoY), while the FY2025 annual figure was -$84.4 million, up 31.06% from the prior year.
- Free Cash Flow came in at -$18.7 million for Q1 2026 at Alx Oncology Holdings, up from -$19.0 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$17.1 million in Q3 2025 to a low of -$39.8 million in Q4 2023.
- A 5-year average of -$26.3 million and a median of -$25.5 million in 2024 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow tumbled 313.52% in 2022 and surged 40.73% in 2025, its largest moves.
- Alx Oncology Holdings' Free Cash Flow stood at -$21.1 million in 2022, then tumbled by 89.13% to -$39.8 million in 2023, then grew by 19.38% to -$32.1 million in 2024, then soared by 40.73% to -$19.0 million in 2025, then climbed by 1.74% to -$18.7 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$18.7 million, -$19.0 million, and -$17.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | -18.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.70 Mn |
| Mar 31, 2026 | -18.70 Mn |
| Dec 31, 2025 | -19.03 Mn |
| Dec 31, 2025 | -19.03 Mn |
| Sep 30, 2025 | -17.15 Mn |
| Sep 30, 2025 | -17.15 Mn |
| Jun 30, 2025 | -23.45 Mn |
| Jun 30, 2025 | -23.45 Mn |
| Mar 31, 2025 | -24.72 Mn |
| Mar 31, 2025 | -24.72 Mn |
| Dec 31, 2024 | -32.11 Mn |
| Dec 31, 2024 | -32.11 Mn |
| Sep 30, 2024 | -25.53 Mn |
| Sep 30, 2024 | -25.53 Mn |
| Jun 30, 2024 | -26.66 Mn |
| Jun 30, 2024 | -26.66 Mn |
| Mar 31, 2024 | -38.07 Mn |
| Mar 31, 2024 | -38.07 Mn |
| Dec 31, 2023 | -39.83 Mn |
| Dec 31, 2023 | -39.83 Mn |
| Sep 30, 2023 | -29.86 Mn |
| Sep 30, 2023 | -29.86 Mn |
| Jun 30, 2023 | -33.45 Mn |
| Jun 30, 2023 | -33.45 Mn |
| Mar 31, 2023 | -28.51 Mn |
| Mar 31, 2023 | -28.51 Mn |
| Dec 31, 2022 | -21.06 Mn |
| Dec 31, 2022 | -21.06 Mn |
| Sep 30, 2022 | -31.08 Mn |
| Sep 30, 2022 | -31.08 Mn |
| Jun 30, 2022 | -17.26 Mn |
| Jun 30, 2022 | -17.26 Mn |
| Mar 31, 2022 | -21.26 Mn |
| Mar 31, 2022 | -21.26 Mn |
| Dec 31, 2021 | -17.75 Mn |
| Dec 31, 2021 | -17.75 Mn |
| Sep 30, 2021 | -25.25 Mn |
| Sep 30, 2021 | -25.25 Mn |
| Jun 30, 2021 | -20.62 Mn |
| Jun 30, 2021 | -20.62 Mn |
| Mar 31, 2021 | -5.14 Mn |
| Mar 31, 2021 | -5.14 Mn |
| Dec 31, 2020 | -13.63 Mn |
| Dec 31, 2020 | -13.63 Mn |
| Sep 30, 2020 | -7.62 Mn |
| Sep 30, 2020 | -7.62 Mn |
| Jun 30, 2020 | -8.11 Mn |
| Jun 30, 2020 | -8.11 Mn |
| Mar 31, 2020 | -8.97 Mn |
| Mar 31, 2020 | -8.97 Mn |
| Dec 31, 2019 | -2.81 Mn |
| Dec 31, 2019 | -2.81 Mn |
| Sep 30, 2019 | -3.19 Mn |
| Sep 30, 2019 | -3.19 Mn |